

ACAAI COVID-19 Vaccine Comparison Chart – 1/13/21

Vaccine	Pfizer-BioNTech	Moderna																																										
Mechanism of action	Vaccine contains 30 mcg of a nucleoside-modified messenger RNA (mod RNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2	Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.																																										
Dose	0.3 ml	0.5 ml																																										
Schedule	2 doses ,21 days apart	2 doses, 28 days apart																																										
Storage	<p>1.Vials must be kept frozen between -80°C to -60°C (-112°F to -76°F) and protected from light.</p> <p>2.If an ultra-low temperature freezer is not available, the thermal container may be used as temporary storage</p> <p>3. Thaw and then store undiluted vials in the refrigerator [2°C to 8°C (35°F to 46°F)] for up to 5 days (120 hours)</p> <p>4 For immediate use, thaw undiluted vials at room temperature [up to 25°C (77°F)] for 30 minutes.</p> <p>5. Undiluted vials may be stored at room temperature for no more than 2 hours.</p>	<p>1.Vaccine multiple-dose vials are stored frozen between -25° to -15°C (-13° to 5°F protected from light, .</p> <p>2.Do not store on dry ice or below -40°C (-40°F).</p> <p>3.Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use.</p> <p>4.Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours.</p> <p>5. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Discard vial after 6 hours. Do not refreeze</p>																																										
Age approved	16 and up	18 and up																																										
Efficacy against COVID-19	7 days after second dose. 18 -64 years- 95.1% 65 years and above 94.7%	14 days after second dose. 18 to < 65 years – 95.6 % >65 years– 86.4 %																																										
VAERS	Mandatory Reporting of adverse events Including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID																																										
Safety Patient self-reporting	Vsafe	Vsafe																																										
Adverse events																																												
Solicited adverse reactions within 7 days after each dose.	<p>Lasted 2-3 days, more adverse reactions after second dose</p> <table border="1"> <thead> <tr> <th></th> <th>Dose 1(%)</th> <th>Dose 2(%)</th> </tr> </thead> <tbody> <tr> <td>Pain at site</td> <td>83.1.</td> <td>77.98</td> </tr> <tr> <td>Fatigue</td> <td>47.4</td> <td>59.4</td> </tr> <tr> <td>Headache</td> <td>41.9</td> <td>51.7</td> </tr> <tr> <td>Myalgia</td> <td>21.3</td> <td>37.3</td> </tr> <tr> <td>Chills</td> <td>14.0</td> <td>35.1</td> </tr> <tr> <td>Arthralgia</td> <td>11.0.</td> <td>21.9</td> </tr> </tbody> </table>		Dose 1(%)	Dose 2(%)	Pain at site	83.1.	77.98	Fatigue	47.4	59.4	Headache	41.9	51.7	Myalgia	21.3	37.3	Chills	14.0	35.1	Arthralgia	11.0.	21.9	<p>Lasted 2-3 days, more adverse reactions after second dose</p> <table border="1"> <thead> <tr> <th></th> <th>Dose 1(%)</th> <th>Dose 2(%)</th> </tr> </thead> <tbody> <tr> <td>Pain at site</td> <td>86.9.</td> <td>89.9</td> </tr> <tr> <td>Fatigue.</td> <td>38.</td> <td>67.6</td> </tr> <tr> <td>Headache</td> <td>24.5.</td> <td>19.3</td> </tr> <tr> <td>Myalgia.</td> <td>23.7</td> <td>61.6</td> </tr> <tr> <td>Chills</td> <td>9.2.</td> <td>8.6</td> </tr> <tr> <td>Arthralgia</td> <td>16.6</td> <td>45.5</td> </tr> </tbody> </table>		Dose 1(%)	Dose 2(%)	Pain at site	86.9.	89.9	Fatigue.	38.	67.6	Headache	24.5.	19.3	Myalgia.	23.7	61.6	Chills	9.2.	8.6	Arthralgia	16.6	45.5
	Dose 1(%)	Dose 2(%)																																										
Pain at site	83.1.	77.98																																										
Fatigue	47.4	59.4																																										
Headache	41.9	51.7																																										
Myalgia	21.3	37.3																																										
Chills	14.0	35.1																																										
Arthralgia	11.0.	21.9																																										
	Dose 1(%)	Dose 2(%)																																										
Pain at site	86.9.	89.9																																										
Fatigue.	38.	67.6																																										
Headache	24.5.	19.3																																										
Myalgia.	23.7	61.6																																										
Chills	9.2.	8.6																																										
Arthralgia	16.6	45.5																																										

ACAAI COVID-19 Vaccine Comparison Chart – 1/13/21

<p>Unsolicited</p>	<p>12 cases of appendicitis reported Anaphylaxis -reported after EUA with first dose</p>	<p>a). 3 cases of Bell’s palsy reported 22,28, 32 days after vaccination – b). 2 cases Facial swelling in vaccine recipients with history of dermatological fillers in 1-2 days c). 1 case of nausea, vomiting 1 day after vaccination d) allergic reaction being investigated after EUA with first dose</p>
<p>Ingredients</p>	<p>1.Lipids - 0.43 mg (4-hydroxybutyl)azanediyl), bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000], N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, 0.2 mg cholesterol) 2.0.01 mg potassium chloride, 3.0.01 mg monobasic potassium phosphate 4. 0.36 mg sodium chloride 5. 0.07 mg dibasic sodium phosphate dihydrate, 6. 6 mg sucrose</p>	<p>1.Lipids- 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 ,dimyristoyl glycerol [DMG], cholesterol,1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) 2. 0.31 mg tromethamine, 3.1.18 mg tromethamine hydrochloride, 4..043 mg acetic acid, 0.12 mg sodium acetate 5.43.5 mg sucrose.</p>